A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-Valent Pneumococcal Conjugate Vaccine in Alaska Native Children.
Phase of Trial: Phase III
Latest Information Update: 09 Feb 2012
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Pfizer; Wyeth
- 22 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.